Regarding “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial”

We read with great interest the article titled ‘‘Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial’’ by Cao et al.1 The study, which finally included 41 patients, evaluated the efficacy and safety of ruxolitinib for severe COVID-19 cases. They finally found that ruxolitinib recipients had a significant chest computed tomography (CT) improvement, a faster recovery from lymphopenia, and favorable side-effect profile. However, we think it is appropriate to comment on the methods used in this study.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Correspondence Source Type: research